Cristina Silva reporting for Newsweek stated that the National Institutes of Health’s Annual Report to the Nation on the Status of Cancer indicated “death rates for the most common types of cancer dropped for men, women and children from all racial and ethnic backgrounds from 2010-2014.” Investigators found that “the rates of new cancers were lower for men but held steady for women.”
Comment: As newer therapies are developed, we are slowly beating back this old enemy.
Dr. Jonathan Kay elegantly summarized the answer to this perplexing question on Medscape. He said, “Patients with rheumatoid arthritis appear to be at higher risk of developing lymphoma — both Hodgkin and non-Hodgkin lymphoma — and lung cancer, and at a potentially decreased risk of developing colorectal and breast cancer compared with the general population. The risk of developing lymphoma is associated with disease activity and functional class. Patients treated with TNF inhibitors do not have a significantly higher risk of developing malignancy than patients treated with traditional disease-modifying antirheumatic drugs. Treatment of patients who had prior melanoma with TNF inhibitors has been found in the British Society for Rheumatology Biologics Register to have been associated with more incident malignancy and recurrent metastases. The risks associated with biologic agents should be weighed against their potential benefits in patients with previous malignancy as they should be done in any patient with rheumatoid arthritis.”
Comforting news from a well-respected rheumatologist.
Simeon Bennett writing in Bloomberg News reported that individuals “who took a daily dose of aspirin had a 24 percent lower rate of developing cancer after three years and were 37 percent less likely to die from the disease after five years than those who didn’t, according to a study in The Lancet.” This “rate was similar for men and women.” Two additional “studies published in The Lancet and The Lancet Oncology… showed that aspirin reduced the risk of any cancer spreading to other organs by 36 percent and certain types of tumors by 46 percent.” Comment: Aspirin… the wonder drug!
Scott Pelley reporting for CBS reported on a trial involving over 35,000 men, ” to see if vitamin E and selenium could prevent prostate cancer.” In 2008, it was found that neither vitamin E nor selenium “prevented cancer and everyone was told to stop taking the vitamins.” Then it was found that “men who took vitamin E alone were at a 17% increased risk of developing prostate cancer.”
Metal-On-Metal Hip Replacements May Not Be Linked To Increased Cancer Risk.
Alison Connoly writing in Bloomberg News reported “Patients who received metal-on-metal hip replacements are at no greater risk of developing cancer after a seven-year period than those with alternatives or the general population, according to a study” published online in the British Medical Journal. Good news for once with these replacements.